Roles
- Chairman and Harvey Blank Professor
- Dr. Phillip Frost Dept. of Dermatology and Cutaneous Surgery
- Professor, Department of Public Health Sciences
- Director, University of Miami Hospital and Clinics Wound Center
- Chief of Dermatology at the University of Miami Hospitals and at Jackson Memorial Hospital
- Director, University of Miami Wound Clinic
-
Biography
Dr. Kirsner is Chairman and the endowed Harvey Blank Professor in the Dr. Phillip Frost Dermatology in the Department of Dermatology and Cutaneous Surgery and Professor of Public Health Sciences at the University of Miami Miller School of Medicine. He is Chief of Dermatology at the University of Miami Hospital and Clinics and Jackson Memorial Hospital and directs the University of Miami Hospital Wound Center. Dr. Kirsner received his undergraduate degree from Texas A&M University, his medical degree from the University of Miami and a PhD in epidemiology from the University of Miami, after he completed his clinical training. His clinical training included internal medicine, a clinical and research fellowship in wound healing and dermatology at the University of Miami. Dr. Kirsner serves as one of 3 academic editors for the journal Wound Repair and Regeneration and on the editorial boards for a number of other journals in dermatology and wound healing. Dr. Kirsner serves in national leadership positions in both Wound Healing and Dermatology, including being Vice President of the American Academy of Dermatology and serving on the Wound Healing Society Board of Directors. In addition to career development awards, foundation, industry sponsored funding and CDC funding, he currently leads or is part of a number of NIH funded grants. Independent of books, book chapters and abstracts, he has published over 550 articles. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Teaching Interests
Dr. Kirsner teaches medical students, residents, fellows, masters students, doctoral students, and postgraduates. -
Research Interests
Dr. Kirsner's research interests include Wound Healing and Skin Cancer Epidemiology. In wound healing, he uses translational approaches to understand the pathophysiology and explore new treatments for chronic wounds such as diabetic foot ulcers and venous leg ulcers. In skin cancer epidemiology, he uses epidemiological approaches to define and address skin cancer disparities. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
Building Global Research Connections
A Globally Renowned Wound Healing Program
A Family’s Gift Honors Their Grandparents
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 8 clinical trials.
-
The purpose of this proposal is to demonstrate the feasibility of a new device that allows totally non-invasive tissue blood flow imaging to detect changes in blood flow in wound ulcers. This device will be tested on patients being treated at the Jackson South Community Hospital and University of Miami Hospital wound care clinics. The objectives and specific aims of this study are to 1) test the utility of this new totally non-invasive hand held near infrared spectroscopy (NIRS) optical imaging technology to quantify peripheral blood flow in patients with lower extremity vascular disease from any cause. 2) We will collect data on static and/or dynamic real-time visual images of the distribution of blood flow in healthy and diseased tissues. 3) This device will enable physicians and researchers to monitor changes in the adequacy of blood flow over time in affected regions of the body that result from physiological, pathophysiological, or therapeutic (i.e. efficacy of wound healing treatments) interventions. Description:The optical technique described herein is totally non-invasive and relatively inexpensive, in comparison to the currently available imaging techniques. Wounds that are refractory to standard therapy result from pressure ulcers, diabetic foot ulcers, or in amputees. The estimated number of diabetic cases worldwide is more than 170 million, and projected to continue increasing. The diabetic foot ulcer is a major public health problem and is a consequence of the complications associated with diabetes, with ~15% of diabetic patients developing such foot ulcers. Foot ulceration in diabetic patients is the leading cause of non-traumatic amputation in developed countries worldwide. Hence, foot ulcers are one of the most frequently encountered problems in wound-healing today. Improvements in the ability to rapidly assess whether a treatment is effective or not will help in the development of effective treatments and will have a major impact on this patient population.Hypothesis:Our research hypothesis is that NIR spectroscopy imaging of skin blood flow and oxygenation at the site of diabetic skin ulcers using this new hand held imaging system described in this proposal will simplify, expedite and improve the accuracy of clinical decision making regarding medical and surgical interventions to foster wound healing.
- Principal Investigator: Robert Kirsner
- Study Phase: N/A
- Enrollment Status: Open
-
To evaluate the efficacy of treatment with vilobelimab compared to placebo in patients with PG
- Principal Investigator: Robert Kirsner
- Study Phase: TBD
- Enrollment Status: Closed
-
To assess the safety and efficacy of EscharEx (EX-03 formulation) compared to placebo control, in patients with Venous Leg Ulcers (VLU).
- Principal Investigator: Robert Kirsner
- Study Phase: TBD
- Enrollment Status: Open
-
Arche Healthcare plans to revolutionize home diabetic foot screening by integrating into the existing OPTYX clinical information system, the two following components: the InVision hardware device (modified TempStat) and InFocus mobile App.The device and app usability will be evaluated in 15 patients at high risk of developing a diabetic foot ulcer. Several aspects of usability will be assessed: a) effectiveness (how accurately the tasks were completed and how often they produce errors); b) efficiency (the level of resource consumed in performing tasks) and c) user satisfaction (users’ subjective reactions to using the system).
- Principal Investigator: Robert Kirsner
- Study Phase: N/A
- Enrollment Status: Closed
-
The purpose of this research is to measure the barrier integrity of skin, using a skin water loss test known as trans-epidermal water loss (TEWL) on the healed DFU-site.
- Principal Investigator: Robert Kirsner
- Study Phase: N/A
- Enrollment Status: Closed
-
Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima)
- Principal Investigator: Robert Kirsner
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The primary objective is to demonstrate superiority of spesolimabover placebo in the difference in the proportion of trial participantswith achievement of complete closure (100% PG area reduction,PGAR-100) of the target PG ulcer at any time up to Week 26.
- Principal Investigator: Robert Kirsner
- Study Phase: TBD
- Enrollment Status: Open
-
This study will look at the pharmacokinetics (PK) of HT-001; PK is a measurement of how it enters the bloodstream after it is applied, how long it stays in the bloodstream, how it is metabolized (absorbed in the body), as well as how long it takes to be cleared from your body. This study will also look at how safe, effective, and tolerable (whether side effects can be handled by subjects) HT-001 is compared to placebo in the treatment of skin issues associated with EGFRIs, as well as the impact of HT-001 on subjects quality of life.
- Principal Investigator: Robert Kirsner
- Study Phase: Phase II
- Enrollment Status: Closed